[Comment] Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia

Therapies targeting the B-cell receptor (ie, B-cell receptor inhibitors) are a welcome addition to chronic lymphocytic leukaemia and small lymphocytic lymphoma management. It has shifted the treatment paradigm from one of active chemotherapy to chronic care.1 The ease of administration, without the constraints on age and fitness for chemotherapy, combined with predictable short-term and long-term toxicity profiles, makes B-cell receptor inhibitors an attractive therapy for many patients. Importantly, this class of oral agents has improved equity and access of treatments in all age groups and geographical regions.